DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced it will release its first quarter ended March 31, 2020 financial results on Tuesday, May 12, 2020, and host a conference call at 8:30am Eastern Time.

DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, announced today that in an effort to reduce contact between healthcare providers and patients in hospital settings, limit COVID-19 exposure, and preserve personal protective equipment (PPE), the U.S. Food and Drug Administration (FDA) has recognized that home-use blood glucose meters including Dario's smartphone-connected metering device may be used by patients with diabetes who are hospitalized due to COVID-19 to check their own blood glucose levels and provide the readings to the health care personnel caring for them.

DarioHealth Corp. (Nasdaq: DRIO) ("Dario") a pioneer in the global digital therapeutics market, announced today that it has entered into a partnership with Vitality Group, a global health and wellness company committed to making people healthier. Under the partnership, Vitality will integrate Dario's digital therapeutics for chronic conditions into its current wellness solution platform and co-market the Dario solution to Vitality's existing client base. In conjunction with the partnership, Dario granted Vitality warrants that will become exercisable dependent on the success of the partnership over the next four years, beginning in 2020.

Global digital therapeutics innovation leader DarioHealth Corp. (NASDAQ: DRIO) today announced it will release its fourth quarter and year end 2019 results on Tuesday, March 17, and host a conference call the same morning at 8:30 am EDT.

DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today the appointment of Richard Anderson as its President and General Manager of North America, effective January 13, 2020. Reporting to Chief Executive Officer Erez Raphael, Mr. Anderson will be responsible for both operational and commercial development, focusing primarily on the U.S. market. His appointment marks a key inflection point, supporting DarioHealth's strategic initiatives in the business-to-business (B2B) channel. This is one of many organizational changes that emphasize our focus on this large market. In conjunction with Mr. Anderson's appointment, DarioHealth will transition Olivier Jarry to serve as Senior Vice President of Strategy and Business Development.

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...

The analysts covering DarioHealth Corp. (NASDAQ:DRIO) delivered a dose of negativity to shareholders today, by making...

DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or "Dario"), a pioneer in the global digital therapeutics market, today presented a new clinical study at the Advanced Technologies & Treatments for Diabetes ("ATTD") conference in Madrid, Spain, which showed significant reductions of both hypoglycemic and high glycemic events in people with type 1 and insulin dependent type 2 diabetes using Dario's digital therapeutics platform. The presentation will be available at the conference, on the ATTD 2020 website during the conference, and online for one year following the conference. The accepted abstract will be published in the peer-reviewed journal Diabetes Technology & Therapeutics.

DarioHealth Corp. (Nasdaq: DRIO) ("DarioHealth" or the "Company"), a pioneer in the global digital therapeutics market, announced today that on January 30, 2020, Richard Anderson was granted a non-qualified stock option award to purchase 90,000 shares of the Company's common stock, as well as an additional non-qualified performance-based stock option award to purchase an additional 90,000 shares of the Company's common stock, pursuant to Nasdaq Listing Rule 5635(c)(4) outside of the Company's existing equity compensation plans in connection with Mr. Anderson's previously-announced employment by the Company as its President and General Manager of North America. These options were granted as an inducement material to Mr. Anderson becoming an employee of the Company, in accordance with Nasdaq Listing Rule 5635(c)(4).

DarioHealth Corp. (Nasdaq: DRIO), a leading global digital therapeutics (DTx) innovator, announced today that it has expanded its offering on its chronic care platform application to include behavioral health coaching for stress, anxiety and loneliness, conditions which have recently escalated due to COVID-19 social distancing restrictions including "shelter-in-place" and "stay-at-home" orders.

DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the company has appointed Yadin Shemmer and Adam K. Stern to serve as board members effective immediately until the 2020 Annual Meeting of stock holders.

DarioHealth Corp. (Nasdaq: DRIO), a global digital therapeutics (DTx) innovator, today reported financial results for the fourth quarter and full year ended December 31, 2019 and provided a corporate and commercial update.

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, announced today the appointment of Omar Manejwala, M.D to the newly created position of Chief Medical Officer, and Barbara Stark as Senior Vice President and Head of Managed Markets. These two appointments provide decades of industry and clinical experience to the managed care and clinical support teams.

Shares of DarioHealth (NASDAQ:DRIO) remained unaffected at $7.95 after the company reported Q1 results.Quarterly Results Earnings per share fell 946.67% year over year to ($1.57), which missed the estimate of ($0.75).Revenue of $1,667,000 less by 25.65% year over year, which missed the estimate of $1,750,000.Guidance DarioHealth hasn't issued any earnings guidance for the time being.Revenue guidance hasn't been issued by the company for now.How To Listen To The Conference Call Date: May 12, 2020View more earnings on DRIOTime: 08:04 PM ETWebcast URL: https://www.webcaster4.com/Webcast/Page/2224/34665Technicals Company's 52-week high was at $11.2552-week low: $0.20Price action over last quarter: Up 109.21%Company Overview DarioHealth Corp is a digital health company. It is engaged in the development and commercialization of patented and proprietary technology that provides consumers with laboratory-testing capabilities using smartphones and other mobile devices. The company's product, Dario Blood sugar monitor is a mobile, real-time, cloud-based, diabetes management solution based on a multi-featured software application combined with a blood glucose monitoring device. The group operates internationally and derives revenues from the sale of its Dario smart meter and related device-specific disposables test strip cartridges and lancets. The company generates the majority of the revenue by sales of its product.See more from Benzinga * Stocks That Hit 52-Week Lows On Monday * A Look Into AMC Entertainment's Price Over Earnings * Stocks That Hit 52-Week Highs On Monday(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

Q4 2019 DarioHealth Corp Earnings Call

DarioHealth Corp. (NASDAQ: DRIO), a pioneer in the global digital therapeutics market, announced today the launch of its digital therapeutics solution for managing chronic diseases such as diabetes and hypertension on Albertsons Marketplace.

Long term investing is the way to go, but that doesn't mean you should hold every stock forever. We don't wish...

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in the global digital therapeutics market, today reported financial results for the first quarter 2020 and provided a corporate and commercial update.

DarioHealth Corp. (NASDAQ: DRIO), a global digital therapeutics (DTx) innovator, announced today an endorsement from the U.K. based ORCHA, highlighting the Company's Diabetes Management Application as being suitable and safe for children and young people. In its recommendation, ORCHA mentioned the value of Dario's app in helping parents monitoring their child's diabetes information. The ORCHA team is part of NHS England's National Innovation Accelerator program and supports many NHS and local government organizations to drive the uptake of digital health among their populations.

DarioHealth Corp. (Nasdaq: DRIO), a pioneer in global digital therapeutics (DTx), announced today a new partnership with value-based telemedicine provider MediOrbis to expand Dario's existing service offering with a full suite of telemedicine capabilities for its 50,000 active users.